Table 2

Second-line therapies in patients receiving metformin (as monotherapy or as part of a combination treatment) as a first-line therapy, according to first-line therapy

Second-line therapyFirst-line therapyOverall
n=11 837
MET monotherapy n=8488 (71.7)MET+SU n=2139 (18.1)MET+DPP-4i n=489 (4.1)MET+SU+
DDP-4i n=217 (1.8)
MET+other(s) n=504 (4.3)
Second-line therapy with MET7294 (85.9)1739 (81.3)406 (83.0)184 (84.8)432 (85.7)10 055 (84.9)
 MET monotherapy0 (0.0)22 (1.0)9 (1.8)2 (0.9)2 (0.4)35 (0.3)
 MET+SU2549 (30.0)137 (6.4)23 (4.7)2 (0.9)31 (6.2)2742 (23.2)
 MET+DPP-4i2780 (32.8)243 (11.4)58 (11.9)3 (1.4)56 (11.1)3140 (26.5)
 MET+SU+DPP-4i135 (1.6)588 (27.5)131 (26.8)29 (13.4)37 (7.3)920 (7.8)
 MET+insulin*288 (3.4)214 (10.0)33 (6.7)59 (27.2)79 (15.7)673 (5.7)
 MET+other(s)†1542 (18.2)535 (25.0)152 (31.1)89 (41.0)227 (45.0)2545 (21.5)
Second-line therapy without MET1194 (14.1)400 (18.7)83 (17.0)33 (15.2)72 (14.3)1782 (15.1)
 SU monotherapy322 (3.8)13 (0.6)22 (4.5)1 (0.5)3 (0.6)361 (3.0)
 DPP-4i monotherapy376 (4.4)93 (4.3)6 (1.2)0 (0.0)7 (1.4)482 (4.1)
 Other monotherapy†224 (2.6)183 (8.6)20 (4.1)14 (6.5)27 (5.4)468 (4.0)
 Insulin*61 (0.7)52 (2.4)13 (2.7)9 (4.1)13 (2.6)148 (1.3)
 Other combinations without MET211 (2.5)59 (2.8)22 (4.5)9 (4.1)22 (4.4)323 (2.7)
  • Data are reported as n (%). Percentages were calculated for all patients with data available; patients with missing data were excluded. Switches between two agents in the same class (eg, from an SU to another SU) were considered as treatment changes.

  • *May contain other oral treatments.

  • †Including α-glucosidase inhibitors, thiazolidinediones, meglitinides, sodium–glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.

  • DPP-4i, dipeptidyl peptidase-4 inhibitor; MET, metformin; SU, sulphonylurea.